Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABAb
2022-500085-96-00Phase 3Authorised
- Sponsor
- CHU de Nantes
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gambling disorder (GD), Food addiction, hypersexuality and 1 more comparing Nalmefene (Selincro) + treatment as usual with Placebo + treatment as usual (2 arms). Planned start Aug 2022; status: authorised.
02
Drugs
nalmefene
03
Conditions
gambling disorder (GD)Food addictionhypersexualitybehavioral addiction
Beyond the preview
Go deeper on 2022-500085-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500085-96-00.